Which medication is commonly used to address the thrombotic risk associated with loss of antithrombin III in lymphangiectasia?

Which medication is commonly used to address the thrombotic risk associated with loss of antithrombin III in lymphangiectasia?

• A. Warfarin
• B. Aspirin
• C. Clopidogrel
• D. Heparin

Answer: (C)

When antithrombin III is lost in conditions like lymphangiectasia, the body loses a key natural brake on coagulation, so thrombosis becomes more likely, especially in the venous system. The main way to counter this risk is anticoagulation to reduce the generation of thrombin and the propagation of clots. Heparin is commonly used because it enhances the activity of whatever antithrombin III is still present, helping to inhibit thrombin and factor Xa. In practice, levels of antithrombin III can be low, so the full effect of heparin may require replenishing ATIII or using it as a bridge to longer-term anticoagulation such as warfarin or a direct oral anticoagulant once feasible. Aspirin or clopidogrel, which inhibit platelets, address platelet-driven arterial clots and do not tackle the main issue here, so they’re not the primary choice for preventing venous thrombosis due to ATIII loss.

When antithrombin III is lost in conditions like lymphangiectasia, the body loses a key natural brake on coagulation, so thrombosis becomes more likely, especially in the venous system. The main way to counter this risk is anticoagulation to reduce the generation of thrombin and the propagation of clots. Heparin is commonly used because it enhances the activity of whatever antithrombin III is still present, helping to inhibit thrombin and factor Xa. In practice, levels of antithrombin III can be low, so the full effect of heparin may require replenishing ATIII or using it as a bridge to longer-term anticoagulation such as warfarin or a direct oral anticoagulant once feasible. Aspirin or clopidogrel, which inhibit platelets, address platelet-driven arterial clots and do not tackle the main issue here, so they’re not the primary choice for preventing venous thrombosis due to ATIII loss.